Adjuvant epirubicin and gemcitabine sequential perfusion therapy for non-muscle invasive bladder tumor after transurethral resection
10.3760/cma.j.issn.1006-9801.2014.03.013
- VernacularTitle:经尿道膀胱肿瘤切除术后表柔比星与吉西他滨序贯灌注辅助治疗非肌层浸润性膀胱癌
- Author:
Jun WANG
;
Long HE
;
Long LIU
;
Hongwei YANG
- Publication Type:Journal Article
- Keywords:
Bladder neoplasms;
Chemotherapy,cancer,regional perfusion;
Epirubicin;
Gemcitabine
- From:
Cancer Research and Clinic
2014;26(3):187-189
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the safety and efficacy of epirubicin (EPI) and gemcitabine (GEM) alternating sequential intravesical chemotherapy after transurethral resection in the treatment of non-muscle invasive bladder cancer.Methods 240 patients with primary non-muscle invasive bladder urothelial carcinoma were randomly divided into 2 groups.There were 120 cases for each group,EPI group was given EPI 50 mg (once a week),bladder perfusion,while the EPI+GEM group was given EPI 50 mg (once every other week),GEM 1000 mg (once every other week),alternating sequential perfusion.The follow-up time ranged from 6 to 24 months when the time of tumor recurrence and adverse reactions of chemotherapy were observed and recorded.Results The 2-year tumor free survival rate for EPI group recurrence was 60.0 ％ (72/120),and 75.0 ％ (90/120) for EPI+GEM group.There were statistical significance between the differences of the 2 groups (x2 =5.489,P ＜ 0.05).3 cases in EPI group and 2 cases in EPI+GEM group progressed to muscle invasive bladder cancer,and there was no statistical significance between the differences of bladder cancer progression rates for the 2 groups (2.5 ％ and 1.7 ％) (x2 =0.000,P ＜ 0.05).The main adverse reaction during the treatment was gastrointestinal discomfort (15 cases and 6 cases respectively),no serious haematological toxicity and other adverse reactions were frequent urination,urgency,dysuria and hematuria.The differences between the occurrence rates of adverse reactions for the 2 groups were 25.0 ％ and 11.7 ％,which were statistically significant (x2 =6.252,P ＜ 0.05).Conclusion For non-muscle invasive urothelial bladder carcinoma,the curative effect is better to use EPI and GEM sequential intravesical chemotherapy than to use EPI alone,which can not only reduce the 2 years recurrence rate after the operation,but also reduce the incidence rate of adverse reactions.Yet,this method cannot change the progress of bladder cancer.
